|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Industry: Key Events and Trends Shaping its Current Status and Future Direction
Datamonitor, March 2006, Pages: 87
Despite a tough year in 2005 in terms of the regulatory environment and public opinion, with the withdrawal of Vioxx still at the forefront of peoples minds, a number of leading pharmas continued to drive impressive growth. Biologicals continued to lead the market in terms of growth with Genentechs cancer focused portfolio driving the fastest growth in 2005 and forecast to do the same in 2006.
Scope of this title:
- Examines the performance of the leading pharma companies in 2005 to reveal the winners and losers by sales growth and share price performance
- Identifies the products driving market growth and considers the patent expiries that are expected to slow that growth over the coming year
- Explores the key trends that will shape the pharmaceutical market in 2006 and beyond
Highlights of this title:
Genentech was the fastest growing of the top 50 pharma and biotech companies in 2005. The company has been one of the major success stories of the last few years, and backs up that reputation with an impressive 46.4% sales growth rate in 2005, building on sales of $3,749m in 2004. It is also forecast to have the fastest growth in 2006.
2005 was characterized by a lack of mega-mergers between the industry heavyweights, as the major players questioned the value of such huge-scale deals. Nevertheless, it has remained popular to make small, incremental acquisitions to acquire pipeline products or increase presence in specific therapeutic areas a trend expected to continue
While there were a number of new product launches in 2005, 2006 looks set to see the launch of products with greater potential. Sanofi-Aventis Acomplia for the treatment of obesity and smoking cessation and Pfizers inhalable insulin Exubera both have considerable sales potential
Reasons to order your copy:
- Benchmark the leading companies in terms of sales and share price performance in 2005
- Uncover the products driving growth in the pharmaceutical industry as well as the key patent expiries likely to restrict it
- Assess the key trends that will shape the future pharmaceutical market
Customers who bought this item also bought
Forecast Insight: Antihypertensives - Key Patent Expiries Prevent Market Growth
Winning Product Launch Strategies: Maximizing sales from new pharmaceutical products
Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries
The Fastest Growing Biotechnology Companies: Growth Strategies, Comparative Analyses and Company Profiles
Licensing Strategies - Examining Today�s Pharmaceutical Licensing Trends
Innovation in the USA: New product launches, key trends and leading companies in FMCG for 2005
Commercial Insight: Cytotoxic Therapy Cancer Brands - Looming Patent Expiries Limit Market Growth
Winners and Losers in the Japanese Pharmaceutical Market
Commercial Insight: Antidiabetics Patent expiries and cost containment initiatives balanced by pipeline products
Licensing Strategies: Trends In The Top 20 Pharmaceutical Companies Activity
The Top Ten Specialty Pharmaceutical Companies: Positioning, Performance and SWOT Analyses
Pharmaceutical And Biotech Growth Strategies: Future Drivers And Opportunities
|
|
|
|
